 Kazia Therapeutics Ltd ASX:KZA, NASDAQ:KZIA has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationships with US investors, preparing the company for future expansion and raising the profile of Kazia in global markets. KZAs lead program is paxalisib, a brain-penetrant inhibitor of the PI3KAktmTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. 